Clinical Trial Update: Does CERC-501 Attenuate Stress-precipitated Smoking Lapse? [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether CERC-501 reduces smoking lapse triggered by stress; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoking Cessation

Drugs mentioned

• CERC-501

Snippet

Sponsor: Yale University | Conditions: Smoking | Phase 2 | Status: COMPLETED | Results posted: 2019-08-13